Pharma company, global service provider partner to develop neuroscience disorder therapies

Neuroscience specialty pharmaceutical company OWP Pharmaceuticals Inc. has partnered with Eversana, a provider of global services to the life sciences industry, to launch oral liquid formulations for treating neuroscience disorders.

According to a press release, OWP is currently developing multiple specialty pharmaceutical products that are pending regulatory approvals. The company most recently received investigational new drug (IND) authorization for its novel oral liquid formulation of atomoxetine hydrochloride for treating ADHD. It also received patent issuance or IND authorization for treatments related to epilepsy, schizophrenia, bipolar disorder, major depressive and generalized anxiety disorder and migraines.

OWP will make use of Eversana’s commercialization services, including those related to market access, agency services, clinical and commercial field teams, channel management, patient services, health economics and outcomes research, and compliance.

“With Eversana’s integrated commercialization solution, we are ensuring that our products will get to patients efficiently and effectively as we anticipate multiple regulatory approvals in 2023 and beyond,” Scott Boyer, founder and president of OWP, said in the release.